US2022387413A1PendingUtilityA1

Antiproliferative compounds and methods of use thereof

79
Assignee: CELGENE CORPPriority: Jul 11, 2014Filed: Dec 23, 2021Published: Dec 8, 2022
Est. expiryJul 11, 2034(~8 yrs left)· nominal 20-yr term from priority
A61K 31/454C07D 209/34A61P 35/00C07D 401/14C07D 401/04A61K 31/506A61K 45/06A61P 37/06A61K 31/501A61K 31/4545A61K 31/5377A61P 31/04A61P 7/00A61K 31/496C07B 2200/13A61P 43/00A61P 37/02A61P 35/02
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds of formula I for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed.

Claims

exact text as granted — not AI-modified
1 - 24 . (canceled) 
     
     
         25 . Compound N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoro-2-(p-tolyl)acetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. 
     
     
         26 . A pharmaceutical composition comprising the compound of claim  1  and a pharmaceutically acceptable excipient. 
     
     
         27 . A method of treating leukemia in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of  claim 25 . 
     
     
         28 . The method of  claim 27 , wherein the leukemia is chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia or acute myeloid leukemia. 
     
     
         29 . The method of  claim 28 , wherein the leukemia is an acute myeloid leukemia. 
     
     
         30 . The method of  claim 27 , wherein the leukemia is relapsed, refractory or resistant to conventional therapy. 
     
     
         31 . The method of  claim 27 , further comprising administering a therapeutically effective amount of another second active agent or a support care therapy. 
     
     
         32 . The method of  claim 31 , wherein the other second active agent is a therapeutic antibody that specifically binds to a cancer antigen, hematopoietic growth factor, cytokine, anti-cancer agent, antibiotic, cox-2 inhibitor, immunomodulatory agent, immunosuppressive agent, corticosteroid or a pharmacologically active mutant or derivative thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.